Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation for postherpetic neuralgia is limited primarily due to its relatively low incidence and the variability in patient experiences. As PHN affects fewer individuals compared to more prevalent conditions, comprehensive clinical studies have been sparse. Additionally, the complexity of pain management and the subjective nature of pain perception contribute to the challenges in establishing a standardized clinical profile.
To manage postherpetic neuralgia effectively, consider consulting a pain specialist or a neurologist with experience in treating neuropathic pain. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. While there are no specific patient organizations identified for PHN, participating in clinical trials may offer access to new treatments and contribute to research. You may also explore opportunities for registry participation to help advance understanding of this condition.
There are currently 31 active clinical trials investigating various aspects of postherpetic neuralgia. Notably, several drugs have received orphan drug designation, including amitriptyline, ketamine, and capsaicin. Gabapentin enacarbil is an FDA-approved treatment option. For more information on ongoing trials, you can visit the following link: https://clinicaltrials.gov/search?cond=postherpetic%20neuralgia.
Actionable guidance for navigating care for postherpetic neuralgia
To manage postherpetic neuralgia effectively, consider consulting a pain specialist or a neurologist with experience in treating neuropathic pain. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. While there are no specific patient organizations identified for PHN, participating in clinical trials may offer access to new treatments and contribute to research. You may also explore opportunities for registry participation to help advance understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation for postherpetic neuralgia is limited primarily due to its relatively low incidence and the variability in patient experiences. As PHN affects fewer individuals compared to more prevalent conditions, comprehensive clinical studies have been sparse. Additionally, the complexity of pain management and the subjective nature of pain perception contribute to the challenges in establishing a standardized clinical profile.
To manage postherpetic neuralgia effectively, consider consulting a pain specialist or a neurologist with experience in treating neuropathic pain. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. While there are no specific patient organizations identified for PHN, participating in clinical trials may offer access to new treatments and contribute to research. You may also explore opportunities for registry participation to help advance understanding of this condition.
There are currently 31 active clinical trials investigating various aspects of postherpetic neuralgia. Notably, several drugs have received orphan drug designation, including amitriptyline, ketamine, and capsaicin. Gabapentin enacarbil is an FDA-approved treatment option. For more information on ongoing trials, you can visit the following link: https://clinicaltrials.gov/search?cond=postherpetic%20neuralgia.
Actionable guidance for navigating care for postherpetic neuralgia
To manage postherpetic neuralgia effectively, consider consulting a pain specialist or a neurologist with experience in treating neuropathic pain. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. While there are no specific patient organizations identified for PHN, participating in clinical trials may offer access to new treatments and contribute to research. You may also explore opportunities for registry participation to help advance understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation for postherpetic neuralgia is limited primarily due to its relatively low incidence and the variability in patient experiences. As PHN affects fewer individuals compared to more prevalent conditions, comprehensive clinical studies have been sparse. Additionally, the complexity of pain management and the subjective nature of pain perception contribute to the challenges in establishing a standardized clinical profile.
To manage postherpetic neuralgia effectively, consider consulting a pain specialist or a neurologist with experience in treating neuropathic pain. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. While there are no specific patient organizations identified for PHN, participating in clinical trials may offer access to new treatments and contribute to research. You may also explore opportunities for registry participation to help advance understanding of this condition.
There are currently 31 active clinical trials investigating various aspects of postherpetic neuralgia. Notably, several drugs have received orphan drug designation, including amitriptyline, ketamine, and capsaicin. Gabapentin enacarbil is an FDA-approved treatment option. For more information on ongoing trials, you can visit the following link: https://clinicaltrials.gov/search?cond=postherpetic%20neuralgia.
Actionable guidance for navigating care for postherpetic neuralgia
To manage postherpetic neuralgia effectively, consider consulting a pain specialist or a neurologist with experience in treating neuropathic pain. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. While there are no specific patient organizations identified for PHN, participating in clinical trials may offer access to new treatments and contribute to research. You may also explore opportunities for registry participation to help advance understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 10 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.